It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMPH’s FA Score shows that 0 FA rating(s) are green whileEVOK’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMPH’s TA Score shows that 4 TA indicator(s) are bullish while EVOK’s TA Score has 2 bullish TA indicator(s).
AMPH (@Pharmaceuticals: Other) experienced а -1.82% price change this week, while EVOK (@Pharmaceuticals: Other) price change was +4.76% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.23%. For the same industry, the average monthly price growth was +2.88%, and the average quarterly price growth was -9.56%.
AMPH is expected to report earnings on May 08, 2025.
EVOK is expected to report earnings on Nov 08, 2024.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
AMPH | EVOK | AMPH / EVOK | |
Capitalization | 2.11B | 5.17M | 40,843% |
EBITDA | 240M | -7.29M | -3,291% |
Gain YTD | -3.851 | -0.452 | 851% |
P/E Ratio | 16.69 | N/A | - |
Revenue | 644M | 5.18M | 12,430% |
Total Cash | 257M | 4.74M | 5,423% |
Total Debt | 624M | 5M | 12,480% |
AMPH | EVOK | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 52 | 76 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 67 Overvalued | 52 Fair valued | |
PROFIT vs RISK RATING 1..100 | 52 | 100 | |
SMR RATING 1..100 | 40 | 100 | |
PRICE GROWTH RATING 1..100 | 86 | 85 | |
P/E GROWTH RATING 1..100 | 94 | 82 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EVOK's Valuation (52) in the Pharmaceuticals Other industry is in the same range as AMPH (67). This means that EVOK’s stock grew similarly to AMPH’s over the last 12 months.
AMPH's Profit vs Risk Rating (52) in the Pharmaceuticals Other industry is somewhat better than the same rating for EVOK (100). This means that AMPH’s stock grew somewhat faster than EVOK’s over the last 12 months.
AMPH's SMR Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for EVOK (100). This means that AMPH’s stock grew somewhat faster than EVOK’s over the last 12 months.
EVOK's Price Growth Rating (85) in the Pharmaceuticals Other industry is in the same range as AMPH (86). This means that EVOK’s stock grew similarly to AMPH’s over the last 12 months.
EVOK's P/E Growth Rating (82) in the Pharmaceuticals Other industry is in the same range as AMPH (94). This means that EVOK’s stock grew similarly to AMPH’s over the last 12 months.
AMPH | EVOK | |
---|---|---|
RSI ODDS (%) | 5 days ago74% | 5 days ago90% |
Stochastic ODDS (%) | 5 days ago57% | 5 days ago80% |
Momentum ODDS (%) | 5 days ago66% | 5 days ago90% |
MACD ODDS (%) | 5 days ago65% | 5 days ago90% |
TrendWeek ODDS (%) | 5 days ago76% | 5 days ago90% |
TrendMonth ODDS (%) | 5 days ago65% | 5 days ago79% |
Advances ODDS (%) | 5 days ago73% | 16 days ago81% |
Declines ODDS (%) | 12 days ago67% | 6 days ago90% |
BollingerBands ODDS (%) | N/A | 5 days ago90% |
Aroon ODDS (%) | 5 days ago60% | N/A |
A.I.dvisor tells us that AMPH and AMRX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AMPH and AMRX's prices will move in lockstep.
Ticker / NAME | Correlation To AMPH | 1D Price Change % | ||
---|---|---|---|---|
AMPH | 100% | +0.11% | ||
AMRX - AMPH | 31% Poorly correlated | -0.60% | ||
EOLS - AMPH | 27% Poorly correlated | -0.94% | ||
DVAX - AMPH | 27% Poorly correlated | +0.48% | ||
ORGO - AMPH | 27% Poorly correlated | +0.30% | ||
HROW - AMPH | 27% Poorly correlated | +1.17% | ||
More |
A.I.dvisor tells us that EVOK and PRFX have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EVOK and PRFX's prices will move in lockstep.
Ticker / NAME | Correlation To EVOK | 1D Price Change % | ||
---|---|---|---|---|
EVOK | 100% | -1.35% | ||
PRFX - EVOK | 26% Poorly correlated | -7.08% | ||
SBFM - EVOK | 25% Poorly correlated | +2.42% | ||
CYTH - EVOK | 22% Poorly correlated | +2.37% | ||
SIGA - EVOK | 21% Poorly correlated | -0.24% | ||
AMPH - EVOK | 11% Poorly correlated | +0.11% | ||
More |